Breaking News Instant updates and real-time market news.

MRK

Merck

$62.77

0.11 (0.18%)

17:03
10/09/16
10/09
17:03
10/09/16
17:03

Merck reports data from KEYNOTE-024, KEYNOTE-021

Merck announced results from two studies of KEYTRUDA in the first-line treatment of patients with metastatic non-small cell lung cancer at the ESMO 2016 Congress. In KEYNOTE-024, which evaluated squamous and non-squamous NSCLC patients whose tumors expressed high levels of PD-L1, KEYTRUDA provided a 50 percent reduction in the risk of disease progression or death and a 40 percent reduction in the risk of death compared to platinum doublet, the current standard of care. The median follow-up was 11.2 months. The median PFS for KEYTRUDA was 10.3 months compared to 6.0 months for chemotherapy. At six months, 62.1 percent of patients treated with KEYTRUDA were alive and had no disease progression compared to 50.3 percent of those receiving chemotherapy. This benefit was observed in all study subgroups. ORR was 44.8 percent for patients receiving KEYTRUDA, including six complete responses, compared to 27.8 percent with chemotherapy, including one complete response. The median duration of response was not reached with KEYTRUDA, with a range of 1.9+ to 14.5+ months. The median duration of response with the chemotherapy group was 6.3 months. Median time to response was 2.2 months for both groups. The safety of KEYTRUDA was consistent with what has been seen in previous trials among patients with metastatic NSCLC. There was one treatment-related death in a patient receiving KEYTRUDA -- cause unknown. In KEYNOTE-021, Cohort G, which included patients with metastatic non-squamous NSCLC regardless of PD-L1 expression level, KEYTRUDA plus chemotherapy -- carboplatin plus pemetrexed -- achieved a 55 percent objective response rate compared to 29 percent for chemotherapy alone, the standard of care, and reduced the risk of disease progression or death by 47 percent. All responses were partial. Median duration of response was not reached in either group, with a range of 1.4+-13.0+ for KEYTRUDA plus chemotherapy and 1.4+-15.2+ for chemotherapy alone. Responses in both groups were durable, with 88 percent of responders in the KEYTRUDA plus chemotherapy group and 78 percent of responders in the chemotherapy alone group experiencing ongoing response at the time of data cut-off. Additionally, the KEYTRUDA combination significantly reduced the risk of disease progression or death compared to chemotherapy alone. Median PFS was 13.0 months with KEYTRUDA plus chemotherapy compared to 8.9 months with chemotherapy alone. OS was similar between the two arms, with 92 percent survival at six months in both, and 75 percent and 72 percent survival at 12 months in the KEYTRUDA combination and chemotherapy alone, respectively. Of treated patients on the KEYTRUDA plus chemotherapy arm, 47 percent remained on treatment as of the cut-off date, compared to 31 percent on chemotherapy alone. Of the treated patients who discontinued treatment on the chemotherapy-only arm, 52 percent subsequently received anti-PD-L1 therapy, with 32 percent crossing over to KEYTRUDA monotherapy as allowed by the study protocol and 19 percent receiving it outside of study crossover. The most common immune-mediated adverse events in patients receiving KEYTRUDA plus chemotherapy were hypothyroidism and hyperthyroidism. Additionally, pneumonitis, infusion reactions, and severe skin toxicity were noted. These immune-mediated adverse events occurred at similar rates to patients receiving KEYTRUDA as a single agent. There was one treatment-related death from sepsis in a patient receiving KEYTRUDA plus chemotherapy, and two -- one from sepsis and one from pancytopenia -- in patients receiving chemotherapy alone.

  • 25

    Oct

  • 06

    Nov

MRK Merck
$62.77

0.11 (0.18%)

09/21/16
FBCO
09/21/16
UPGRADE
Target $41
FBCO
Outperform
Clovis upgraded to Outperform from Neutral at Credit Suisse
Credit Suisse analyst Kennen MacKay upgraded Clovis Oncology (CLVS) to Outperform and raised his price target for the shares to $41 from $19. Clovis closed yesterday up 13%, or $3.92, to $34.83. The potential for a takeover "outweighs concerns surrounding patent life, limited experience in platinum resistant/refractory patients, and PARPi competition," MacKay tells investors in a research note. Clovis could be worth $35-$41 per share in a buyout on operational synergies, and $52-$55 per share with leveraged tax benefits, MacKay estimates. He points out that Eli Lilly (Lill)y, Merck (MRK), Japan's Takeda and others have expressed interest in acquiring U.S. oncology companies.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
10/03/16
LEER
10/03/16
NO CHANGE
LEER
Market Perform
AASLD abstracts hint at potential competitive threat to Gilead HCV, says Leerink
Leerink analyst Geoffrey Porges says abstracts for the American Association for the Study of Liver Diseases, or AASLD, meeting revealed very limited efficacy information about the new Hepatitis C regimens for Gilead (GILD), Merck (MRK) and AbbVie (ABBV). Nonetheless, the analyst believes the abstracts hint at the potential competitive threat to Gilead's HCV dominance. While the new 12-week HCV regimens may compete on price, the forthcoming 8-week regimens put the most pressure on Gilead's market share, Porges argues. He reiterates a Market Perform rating on Gilead's shares.
10/07/16
LEER
10/07/16
NO CHANGE
LEER
Outperform
Incyte Epacadostat Phase 1 Melanoma data maturing well, says Leerink
Leerink analyst Michael Schmidt says the data from ECHO-202 Phase 1 study evaluating the combination of Incyte's (INCY) IDO1 inhibitor epacadostat with Merck's (MRK) Keytruda confirms the previously published results and appears to be maturing well. The analyst reiterates an Outperform rating on Incyte's shares, saying Jakafi remains a compelling long-term growth driver for the company, expectations for baricitinib are still moderate, and its maturing oncology pipeline of 14 molecules including epacadostat represents a long-term value driver.

TODAY'S FREE FLY STORIES

EVH

Evolent Health

$25.90

-0.85 (-3.18%)

16:40
06/22/17
06/22
16:40
06/22/17
16:40
Syndicate
Evolent Health files to sell 4.5M shares of Class A common stock for holders »

Goldman Sachs & Co.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IDRA

Idera Pharmaceuticals

$1.73

0.02 (1.17%)

16:34
06/22/17
06/22
16:34
06/22/17
16:34
Hot Stocks
Idera announces FDA orphan drug designation for IMO-2125 for melanoma treatment »

Idera Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:33
06/22/17
06/22
16:33
06/22/17
16:33
General news
Fed Balance Sheet Level data reported »

Week of 6/21 Fed Balance…

16:33
06/22/17
06/22
16:33
06/22/17
16:33
General news
Money Supply M2 Weekly Change data reported »

Week of 6/12 Money Supply…

MGM

MGM Resorts

$33.25

0.29 (0.88%)

16:33
06/22/17
06/22
16:33
06/22/17
16:33
Hot Stocks
Breaking Hot Stocks news story on MGM Resorts »

Soroban Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GS

Goldman Sachs

$219.77

-2.72 (-1.22%)

, BAC

Bank of America

$22.93

-0.2 (-0.86%)

16:32
06/22/17
06/22
16:32
06/22/17
16:32
Hot Stocks
All 34 banks exceed minimum requirements of Fed Stress Test »

Publicly traded banks…

GS

Goldman Sachs

$219.77

-2.72 (-1.22%)

BAC

Bank of America

$22.93

-0.2 (-0.86%)

C

Citi

$63.62

-0.21 (-0.33%)

WFC

Wells Fargo

$52.49

-0.49 (-0.92%)

JPM

JPMorgan

$87.02

-0.1 (-0.11%)

MS

Morgan Stanley

$44.61

-0.3 (-0.67%)

USB

U.S. Bancorp

$51.30

-0.7 (-1.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 14

    Jul

  • 14

    Jul

  • 18

    Jul

  • 19

    Jul

  • 25

    Jul

  • 12

    Oct

  • 12

    Oct

  • 17

    Oct

  • 18

    Oct

  • 15

    Jan

  • 17

    Jan

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

16:30
06/22/17
06/22
16:30
06/22/17
16:30
Options
Preliminary option volume of 14.6M today »

Preliminary option volume…

GOOG

Alphabet

$957.09

-2.36 (-0.25%)

, GOOGL

Alphabet Class A

$976.62

-1.97 (-0.20%)

16:27
06/22/17
06/22
16:27
06/22/17
16:27
Hot Stocks
YouTube developing 'VR180' video format, says team working with camera makers »

Alphabet's (GOOG)…

GOOG

Alphabet

$957.09

-2.36 (-0.25%)

GOOGL

Alphabet Class A

$976.62

-1.97 (-0.20%)

LNVGY

Lenovo

$12.85

0.059 (0.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

BBBY

Bed Bath & Beyond

$33.73

0.07 (0.21%)

16:25
06/22/17
06/22
16:25
06/22/17
16:25
Hot Stocks
Breaking Hot Stocks news story on Bed Bath & Beyond »

Bed Bath & Beyond…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 29

    Jun

NAT

Nordic American Tankers

$6.00

-0.02 (-0.33%)

16:25
06/22/17
06/22
16:25
06/22/17
16:25
Syndicate
Breaking Syndicate news story on Nordic American Tankers »

Nordic American Tankers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JONE

Jones Energy

16:25
06/22/17
06/22
16:25
06/22/17
16:25
Hot Stocks
Jones Energy exits Arkoma Basin with non-core asset sales »

Jones Energy announced …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

GBL

GAMCO Investors

$29.89

0.27 (0.91%)

, CIR

CIRCOR

$58.20

2.98 (5.40%)

16:24
06/22/17
06/22
16:24
06/22/17
16:24
Hot Stocks
Breaking Hot Stocks news story on GAMCO Investors, CIRCOR »

Gabelli reports 15.94%…

GBL

GAMCO Investors

$29.89

0.27 (0.91%)

CIR

CIRCOR

$58.20

2.98 (5.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

BBBY

Bed Bath & Beyond

$33.74

0.08 (0.24%)

16:23
06/22/17
06/22
16:23
06/22/17
16:23
Hot Stocks
Bed Bath & Beyond says saw increased 'softness in transactions in stores' in Q1 »

At this time, Bed Bath…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 29

    Jun

CPE

Callon Petroleum

$9.69

-0.06 (-0.62%)

16:21
06/22/17
06/22
16:21
06/22/17
16:21
Hot Stocks
Callon Petroleum appoints Correne S. Loeffler as Interim CFO »

Callon Petroleum has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 14

    Nov

BBBY

Bed Bath & Beyond

$33.74

0.08 (0.24%)

16:21
06/22/17
06/22
16:21
06/22/17
16:21
Hot Stocks
Bed Bath & Beyond repurchased approximately $127M of common stock in Q1 »

During the fiscal 2017…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 29

    Jun

SGH

Smart Global

$16.20

0.45 (2.86%)

16:20
06/22/17
06/22
16:20
06/22/17
16:20
Earnings
Smart Global sees Q4 EPS 62c-66c, consensus 57c »

Sees Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

SNX

SYNNEX

$121.84

1.51 (1.25%)

16:19
06/22/17
06/22
16:19
06/22/17
16:19
Hot Stocks
SYNNEX approves $300M share repurchase program »

SYNNEX has approved an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

AAL

American Airlines

$48.97

0.54 (1.12%)

, HCA

HCA Holdings

$86.14

2.09 (2.49%)

16:19
06/22/17
06/22
16:19
06/22/17
16:19
General news
On The Fly: Top stock stories for Thursday »

Stocks began the session…

AAL

American Airlines

$48.97

0.54 (1.12%)

HCA

HCA Holdings

$86.14

2.09 (2.49%)

PLNT

Planet Fitness

$23.95

0.38 (1.61%)

THC

Tenet

$18.89

1.21 (6.84%)

UNH

UnitedHealth

$186.50

1.58 (0.85%)

HUM

Humana

$237.00

0.79 (0.33%)

AET

Aetna

$152.98

0.88 (0.58%)

RAD

Rite Aid

$3.08

-0.11 (-3.45%)

WBA

Walgreens Boots Alliance

$76.37

-1.75 (-2.24%)

ORCL

Oracle

$50.30

3.97 (8.57%)

SPLS

Staples

$9.20

0.54 (6.24%)

JWN

Nordstrom

$47.48

1.4 (3.04%)

WB

Weibo

$72.25

-4.71 (-6.12%)

SCS

Steelcase

$14.10

-2.2 (-13.50%)

ACN

Accenture

$122.08

-5.03 (-3.96%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 22

    Jun

  • 22

    Jun

  • 26

    Jun

  • 28

    Jun

  • 29

    Jun

  • 07

    Jul

  • 18

    Jul

  • 23

    Aug

BBBY

Bed Bath & Beyond

$33.74

0.08 (0.24%)

16:19
06/22/17
06/22
16:19
06/22/17
16:19
Hot Stocks
Bed Bath & Beyond reports Q1 SSS from customer-facing digital channels up 20%+ »

Comparable sales in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 29

    Jun

SNX

SYNNEX

$121.96

1.62 (1.35%)

16:18
06/22/17
06/22
16:18
06/22/17
16:18
Earnings
SYNNEX sees Q3 non-GAAP EPS $1.94-$2.02, consensus $1.92 »

Sees Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

BBBY

Bed Bath & Beyond

$33.74

0.08 (0.24%)

16:18
06/22/17
06/22
16:18
06/22/17
16:18
Earnings
Bed Bath & Beyond reports Q1 EPS 53c, consensus 66c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 29

    Jun

SNX

SYNNEX

$121.84

1.51 (1.25%)

16:17
06/22/17
06/22
16:17
06/22/17
16:17
Earnings
SYNNEX reports Q2 non-GAAP EPS $2.08, consensus $1.79 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

$NSD

NASDAQ Market Internals

16:17
06/22/17
06/22
16:17
06/22/17
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBBY

Bed Bath & Beyond

$33.74

0.08 (0.24%)

16:16
06/22/17
06/22
16:16
06/22/17
16:16
Hot Stocks
Breaking Hot Stocks news story on Bed Bath & Beyond »

Bed Bath & Beyond…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 29

    Jun

SBUX

Starbucks

$59.51

-0.45 (-0.75%)

16:16
06/22/17
06/22
16:16
06/22/17
16:16
Initiation
Starbucks initiated  »

Starbucks initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.